Genmab Commercial Expansion Opens The Door To New Types Of Deals
Executive Summary
The company's CEO talked to Scrip about the expected US launch of tisotumab vedotin likely later in 2021 and the company's partnering strategy going forward.
You may also be interested in...
Blow To Genmab As It Is Set To Lose Darzalex Royalties Sooner Than Hoped
The Danish firm will stop receiving royalties on Darzalex after 2030 having has lost on two issues heard at an arbitration tribunal, in a significant blow to its finances.
More Small Biotechs Are Launching Drugs On Their Own
Emerging biopharma companies developed and launched 40% of all new drugs that hit the market in the US in 2020, a significant increase from five years ago, according to IQVIA.
MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.